Short reviews of chemogenomic profiling : past, present and beyond

1. Chemogenomic Profiling : Past ,
Present and Beyond
1

2. Introduction…..
• Established tool for
classification of drugs
• Comparison in drug fitness
profiles in collection of
mutants
• Efficient method for target
identification (eg. Profiling in
yeast )
2

3. Mode of
action
facilitates
are :
Increase potency
Higher selectivity
Fewer off target effects
3

4. Types of
profiling
Homozygous
Profiling
( HOP )
> Delete non-essential genes
Haploinsufficiency
profiling
( HIP )
> Exploits increased sensitivity
towards a compound
4

5. Uses of HIP and HOP :
• Fully automated robotic system
• Target identification of anti-fungal compounds
> GGTase I : Shows the conservation of path among different fungal species
> Acetolactate synthase : identified as broad spectrum Anti-fungal activities
> Erg11p : Show clinical and commercial potential of compounds
5

6. > HIP and
HOP
HIP and HOP deletion collection
have been designed for different
fungal species
6

7. CRISPR-Cas9
system
• For quantification of individual
mutants the gene specific
nucleotides gRNA sequence is used
7

8. Substance Inhibit to Celullar target Site of
intervention
Cladosporin Plasmodium falciparum Lysyl – tRNA Blood and liver stage
proliferation
Cyclic depsipeptide
decatransin
HCT116 Sec61-Sec63 Protein translocation and
membrane insertion at ER
Nannocystin A Myxobacteria α-(TEF2) And β-(EFB1) Cancer line cells
Novolactone Yeast ( ScHsp70 , Hsp
NEF(SSE1) , ScHsp90 and
HSF 1 )
Cytosolic and Isoform of
Hsp70
---
8

9. CRISPR – Cas9
system
First quantative experiment performed by
Smith and coworkers
First genome wide CRISPR-Cas9 executed in
mammalian cells to identify cellular target
and mechanism of action of potent broad
spectrum antiviral compound GSK983 .
Demonstrates its applicability in plasmodia
and plants also .
9

10. References
1. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, et al. (1999) Genomic profiling of
drug sensitivities via induced haploinsufficiency. Nat Genet 21: p 278-283.
2. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, et al. (1999) Functional
Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis. Science.
285: 901-906.
3. Giaever G, Chu AM, Ni L, Connelly C, Riles L, et al. (2002) Functional profiling of the
Saccharomyces cerevisiae genome. Nature 418: 387-391.
4. Hoepfner D, Helliwell SB, Sadlish H, Schuierer S, Filipuzzi I, et al. (2014) High-resolution
chemical dissection of a model eukaryote reveals targets, pathways and gene functions.
Microbiological Research 169: 107-120.
5. Pries V, Cotesta S, Riedl R, Aust T, Schuierer S, et al. (2016) Advantages and Challenges of
Phenotypic Screens: The Identification of Two Novel Antifungal Geranylgeranyltransferase I
Inhibitors. J Biomol Screen 21: 306-315.
6. Richie DL, Thompson KV, Studer C, Prindle VC, Aust T, et al. (2013) Identification and
Evaluation of Novel Acetolactate Synthase Inhibitors as Antifungal Agents. Antimicrobial Agents
and Chemotherapy. 57: 2272-2280.
7. Hoepfner D, Karkare S, Helliwell SB, Pfeifer M, Trunzer M, et al. (2012) An Integrated
Approach for Identification and Target Validation of Antifungal Compounds Active against
Erg11p. Antimicrobial Agents and Chemotherapy 56: 4233-4240. 10

11. 11